In the SRX Investor Lunch and Learn presentation from Dec2014 (page 70), SRX stated that at ASCO they expect to see detailed data from the primary AND secondary end points of the trial.
Secondary end point data expected include:
OVERALL Survival (so there may in fact be some OS data presented in less than 2 weeks)
PFS in the liver
Tumour response rate
Hepatic and extra- hepatic response rate
Quality of life
Toxicity and safety
Liver resection rate
In the SRX Investor Lunch and Learn presentation from Dec2014...
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.8¢ |
Change
0.003(1.43%) |
Mkt cap ! $75.34M | |||
| Open | High | Low | Value | Volume |
| 17.8¢ | 17.8¢ | 17.5¢ | $9.047K | 50.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 7293686 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1399496 | 11 |
View Market Depth
| Last trade - 15.01pm 26/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |